// App-Quantinova.ai

530 : Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.

Researchers

Presenter

  • Javier Cortes

Principal Investigators

  • Noelia Martinez Janez

  • Marie-Paule Sablin

  • Jose Alejandro Perez-Fidalgo

  • Patrick Neven

  • Elham Hedayati

  • Alexandra Ballester

  • Marie-Paule Ehrhart

  • Dennis C Huang

  • Thomas Bogenrieder

  • Peter Schmid

Medical Centers

  • Ramon y Cajal University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Ramon y Cajal University Hospital, Madrid, Spain

  • Institut Curie, Paris Cedex, France

  • Hospital Clinico Universitario, Valencia, Valencia, Spain

  • KU Leuven, Leuven, Belgium

  • Karolinska Institutet, Karolinska University Hospital and SweBCG, Stockholm, Sweden

  • Boehringer Ingelheim Espana S.A., Barcelona, Spain

  • Staburo GmbH, Munich, Germany on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

  • Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan

  • Boehringer Ingelheim RCV, Vienna, Austria, and University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany

  • Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • Taiwan

  • Spain

  • Germany

  • United Kingdom

  • France

  • Belgium

  • Sweden

Companies

  • Staburo GmbH

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Insulin-like growth factor

Drug/Treatment

  • Everolimus

  • Exemestane

  • BI-836845

Outcome

  • Unknown

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02123823

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved